專技 - 調劑學與臨床藥學題庫下載題庫

補充： Amphotericin B劑量在Uptodate寫法：
開始治療前，腎功能差 (包含AKI、各種透析等)，都不用調整劑量 (因為活性排除的比例極低)
治療期間造成腎功能差，換用其他抗真菌藥物或換成Liposomal劑型的


原文：https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information?search=Amphotericin%20B&selectedTitle=1~143&usage_type=panel&display_rank=1&kp_tab=drug_general&source=panel_search_result#

Kidney impairment prior to treatment initiation:

Altered kidney function: IV: No dosage adjustment necessary for any degree of kidney impairment (only 2% to 5% excreted in...

補充： Amphotericin B劑量在Uptodate寫法：
開始治療前，腎功能差 (包含AKI、各種透析等)，都不用調整劑量 (因為活性排除的比例極低)
治療期間造成腎功能差，換用其他抗真菌藥物或換成Liposomal劑型的


原文：https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information?search=Amphotericin%20B&selectedTitle=1~143&usage_type=panel&display_rank=1&kp_tab=drug_general&source=panel_search_result#

Kidney impairment prior to treatment initiation:

Altered kidney function: IV: No dosage adjustment necessary for any degree of kidney impairment (only 2% to 5% excreted in biologically active form) (Ref).

Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m²):

Note: Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Younger patients (<55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (Ref).

IV: No dosage adjustment necessary (Ref).

Hemodialysis, intermittent (thrice weekly): Not significantly dialyzable (Ref):

IV: No dosage adjustment necessary (Ref).

Peritoneal dialysis: Not likely to be significantly dialyzable (highly protein bound with poor peritoneal penetration) (Ref):

IV: No dosage adjustment necessary (Ref).

CRRT: IV: No dosage adjustment necessary (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): IV: No dosage adjustment necessary (Ref).

Nephrotoxicity during treatment: Consider switching to an alternative antifungal agent or a lipid-based amphotericin formulation (Ref). However, if continued use of amphotericin B deoxycholate is deemed clinically appropriate, may consider interrupting therapy for 24 to 48 hours, then resume at one-half of the usual daily dose; the dosage may then be increased to the maximally tolerated dose (Ref). This approach will likely decrease amphotericin deoxycholate exposures, and so should be avoided in the acute phase of serious infections (Ref).